Results 151 to 160 of about 2,733 (199)
The evolving mpox threat (2022-2024): clade dynamics, immune evasion, and escalating global health challenges. [PDF]
Front Cell Infect MicrobiolIrfan Khan M +5 more
europepmc +1 more source
Peri-Umbilicated Pseudopustules in Mpox. [PDF]
Oxf Med Case ReportsGupta N +6 more
europepmc +1 more source
Mpox: disease manifestations and therapeutic development. [PDF]
J VirolWang Y +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Tecovirimat Treatment for Monkeypox Virus Keratouveitis
JAMA Ophthalmology, 2023This case report describes tecovirimat treatment for a patient with monkeypox virus–related keratouveitis.
Luciana P S, Finamor +6 more
openaire +2 more sources
Tecovirimat for smallpox infections
Drugs of Today, 2010SIGA Technologies, Inc. is a small biotech company committed to developing novel products for the prevention and treatment of serious viral diseases, with an emphasis on products to combat outbreaks that could result from bioterrorism. With government support, SIGA has developed the necessary infrastructure to successfully advance new antiviral drugs ...
T C, Bolken, D E, Hruby
openaire +2 more sources
Tecovirimat: First Global Approval
Drugs, 2018Tecovirimat (TPOXX®) is an orthopoxvirus-specific antiviral drug developed by SIGA Technologies in conjunction with the US Department of Health and Human Services' Biomedical Advances Research and Development Authority. It acts by inhibiting the activity of the orthopoxvirus VP37 envelope wrapping protein, thereby preventing the formation of egress ...
openaire +2 more sources